Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02183818 · ClinicalTrials.gov registry record

Integrative-omics of the Disordered COPD Small Airway Epithelium

A clinical trial of Smoking and COPD, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
42
Enrollment target
1
Study location

NCT02183818: Completed study of Smoking and COPD, sponsored by Weill Medical College of Cornell University.

NCT02183818 is a study of Smoking and COPD that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 42 participants, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02183818, a study of Smoking and COPD, has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
42 participants
Enrollment target
1
Study location

Study Summary

We aim to use an integrated network systems approach to analyze certain existing small airway epithelium (SAE) omic data sets at the genetic, epigenetic (methylation), gene expression, microRNA and metabolomic levels, to develop an initial model of network connectivities and key network pressure points relevant to SAE biology in health and disease.

Primary Outcome

Using an integrated network systems approach to analyze our extensive existing SAE omic data sets at the genetic, epigenetic (methylation), gene expression, microRNA and metabolomics levels, to develop an initial model of network connectivities and key network pressure points relevant to SAE biology in health and disease.

Conditions Studied

Study Locations (1)

New York

  • Weill Cornell Medical College - New York

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2015-04-06
Est. Completion 2020-10-15

What the finished NCT02183818 record still lists

NCT02183818 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Smoking appearing as the primary indexed condition, and to 0 interventions.

NCT02183818 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02183818 about?

NCT02183818 is a clinical study titled "Integrative-omics of the Disordered COPD Small Airway Epithelium". We aim to use an integrated network systems approach to analyze certain existing small airway epithelium (SAE) omic data sets at the genetic, epigenetic (methylation), gene expression, microRNA and metabolomic levels, to develop an initial model of network connectivities and key network pressure poi...

What is the current status of trial NCT02183818?

This trial is currently completed. The enrollment target is 42 participants. The study started on 2015-04-06. Estimated completion is 2020-10-15.

What conditions does trial NCT02183818 study?

This clinical trial studies the following conditions: Smoking, COPD.

Who is sponsoring clinical trial NCT02183818?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02183818 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02183818's enrollment target sits among peer trials

42 99th of 123 higher than 24 of 123 other Smoking trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02183818, the US trial registry maintained by the National Library of Medicine. NCT02183818 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.